NZ751515B2 - Inhibitors of cellular metabolic processes - Google Patents

Inhibitors of cellular metabolic processes Download PDF

Info

Publication number
NZ751515B2
NZ751515B2 NZ751515A NZ75151517A NZ751515B2 NZ 751515 B2 NZ751515 B2 NZ 751515B2 NZ 751515 A NZ751515 A NZ 751515A NZ 75151517 A NZ75151517 A NZ 75151517A NZ 751515 B2 NZ751515 B2 NZ 751515B2
Authority
NZ
New Zealand
Prior art keywords
inhibitors
metabolic processes
cellular metabolic
compounds
reare
Prior art date
Application number
NZ751515A
Other versions
NZ751515A (en
Inventor
Zenon D Konteatis
Zhihua Sui
Jeremy M Travins
Zhixiong Ye
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/097524 external-priority patent/WO2018039972A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Priority claimed from PCT/US2017/049439 external-priority patent/WO2018045071A1/en
Publication of NZ751515A publication Critical patent/NZ751515A/en
Publication of NZ751515B2 publication Critical patent/NZ751515B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA), wherein RA, RB, RC, RD, and REare defined herein.

Description

INHIBITORS OF CELLULAR METABOLIC PROCESSES

Claims (1)

  1. CLAIM FOR PRIORITY This application claims the benefit of priority to U.S. Application Serial No.
NZ751515A 2016-08-31 2017-08-30 Inhibitors of cellular metabolic processes NZ751515B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2016/097524 WO2018039972A1 (en) 2016-08-31 2016-08-31 Inhibitors of cellular metabolic processes
CNPCT/CN2016/097524 2016-08-31
US201762548738P 2017-08-22 2017-08-22
US62/548,738 2017-08-22
PCT/US2017/049439 WO2018045071A1 (en) 2016-08-31 2017-08-30 Inhibitors of cellular metabolic processes

Publications (2)

Publication Number Publication Date
NZ751515A NZ751515A (en) 2021-02-26
NZ751515B2 true NZ751515B2 (en) 2021-05-27

Family

ID=

Similar Documents

Publication Publication Date Title
MX2019002303A (en) Inhibitors of cellular metabolic processes.
HK1247922A1 (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
ZA201701299B (en) Glycosidase inhibitors
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
IL272762A (en) Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
PT3805233T (en) (r) and (s) enantiomer of n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-carboxamide as irak4 inhibitors for treating cancer and inflammatory diseases
MX2018010192A (en) Glycosidase inhibitors.
MX2018009773A (en) Heteroaryl inhibitors of pad4.
IL261015B (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
MX2018010191A (en) Glycosidase inhibitors.
TN2016000270A1 (en) Heteroaryls and uses thereof.
MX2018015657A (en) Heterocyclic compounds as antibacte rials.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2018001992A (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
UA114417C2 (en) Inhibitors of iap
MX2018005515A (en) 1,4-dicarbonyl-piperidyl derivatives.
WO2017095950A3 (en) Compounds for treating proliferative diseases
NZ751515B2 (en) Inhibitors of cellular metabolic processes
IL283295A (en) Inhibitors of gli1 as therapeutic agents
PH12019500368A1 (en) Inhibitors of cellular metabolic processes
EA201990556A1 (en) CELLULAR METABOLIC INHIBITORS